Jingsong Wang

Nona Biosciences is a global biotechnology company committed to cutting edge technology innovations, and providing a total solution for partners worldwide, from academies, biotech startups to biopharma giants. The integrated antibody discovery services range from antigen preparation, animal immunization, single B cell screening, to antibody lead generation and engineering, developability assessment and pharmacological evaluation, leveraging the advantages of Harbour Mice® platforms and the experienced therapeutic antibody discovery team. Harbour Mice® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Integrating Harbour Mice® and a single B cell cloning platform, Nona Biosciences is focused on driving global inventions of transformative next-generation drugs by diversified partnership strategies. The values of the antibody discovery platforms and flexible partnership models have been well validated.

Chairman, Remuneration Committee. Chairman, Nomination Committee. Frontage Holdings Corporation is a Hong Kong Stock Exchange (HKEX) listed global CRO company. The company provides integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals.

Harbour BioMed is a global biotechnology company discovering and developing innovative therapeutics for cancer with a focus on immuno-oncology. The company’s discovery and development programs are built around its two patented transgenic mouse platforms for human antibody discovery. The company is building its proprietary pipeline internally, through collaborations with co-development partners, and selective preclinical and clinical stage asset in-licensing. Harbour BioMed also licenses the platforms to companies and academic institutions through its Harbour Antibodies subsidiary. Learn more at: http://www.harbourbiomed.com.

Silicon Therapeutics is a computational drug discovery company designing novel therapeutics for the advancement of human health by building the most accurate in silico models of highly implicated human drug targets. Acquired by Roivant in February, 2021.

In collaborating with top investment firms to cultivate investment opportunity and to establish a leading biotech company in China to develop innovative healthcare solutions for patients in China and around the world.

- Oversee and manage all R&D activities and enabling functions in China - Represent Sanofi R&D to all internal and external stakeholders in China

- Develop and implement translational medicine strategy and biomarker plan across Asia Pacific - Establish regional TM function and manage strategic TM resources to fulfill global and regional R&D needs

Rheumatologist

Board Certifications: Internal Medicine, and Rheumatology